Dr Muhunthan Thillai is the CEO and co-founder of Qureight, a company that has developed software to analyse clinical images, data and biomarkers.
The Cambridge-based tech firm works with pharmaceutical companies, hospitals and research organisations. Qureight’s algorithms structure data from clinical trials to provide insights that can improve treatments and speed up the drug approval process. It is currently focused on lung and heart disease patients.
Thillai, a consultant chest physician, founded Qureight with Dr Alessandro Ruggiero in 2018. The company raised £1.5m in seed funding in 2022 and counts investors Cambridge Angels and Ascension among its backers.
In this week’s Founder in Five Q&A, Thillai reveals the most important early hire for Qureight, recalls an experience that taught him about “political motivations” in decision-making, and explains why speaking to investors can be energising rather than draining....